SEARCH

SEARCH BY CITATION

References

  • 1
    Bhatt DL & Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2, 1528.
  • 2
    Jackson SP & Schoenwaelder SM. (2003) Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug Discov 2, 775789.
  • 3
    Lindemann S, Kramer B, Daub K, Stellos K & Gawaz M (2007) Molecular pathways used by platelets to initiate and accelerate atherogenesis. Curr Opin Lipidol 18, 566573.
  • 4
    Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C & Daida H (2002) Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation 105, 912916.
  • 5
    Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C et al. (2000) Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 96, 17981807.
  • 6
    Moroi M, Jung SM, Okuma M & Shinmyozu K. (1989) A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84, 14401445.
  • 7
    Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML et al. (2004) Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 104, 13501355.
  • 8
    Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I et al. (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18, 397399.
  • 9
    Gruner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung SM, Moroi M & Nieswandt B (2005) Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 105, 14921499.
  • 10
    Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C & Zirngibl H (2001) Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 193, 459469.
  • 11
    Schulte V, Rabie T, Prostredna M, Aktas B, Gruner S & Nieswandt B (2003) Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood 10, 39483952.
  • 12
    Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U & Nieswandt B (2003) A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 197, 4149.
  • 13
    Qian MD, Villeval JL, Xiong X, Jandrot-Perrus M, Nagashima K, Tonra J, McDonald K, Goodearl A & Gill D (2002) Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library. Hum Antibodies 11, 97105.
  • 14
    Smethurst PA, Joutsi-Korhonen L, O’Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A et al. (2004) Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 103, 903911.
  • 15
    Siljander PR, Munnix IC, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Farndale RW & Heemskerk JW (2004) Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 103, 13331334.
  • 16
    Matsumoto Y, Takizawa H, Nakama K, Gong X, Yamada Y, Tandon NN & Kambayashi J (2006) Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time. Thromb Haemost 96, 16711675.
  • 17
    Matsumoto Y, Takizawa H, Gong X, Le S, Lockyer S, Okuyama K, Tanaka M, Yoshitake M, Tandon NN & Kambayashi J (2007) Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res 119, 319329.
  • 18
    Li H, Lockyer S, Concepcion A, Gong X, Takizawa H, Guertin M, Matsumoto Y, Kambayashi J, Tandon NN & Liu Y (2007) The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 27, 11991205.
  • 19
    Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T et al. (2008) A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 118, 17851795.
  • 20
    Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL & Jandrot-Perrus M (2003) Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost. 1, 26532662.
  • 21
    Juste M, Muzard J & Billiald P (2006) Cloning of the antibody kappa light chain V-gene from murine hybridomas by bypassing the aberrant MOPC21-derived transcript. Anal Biochem 349, 159161.
  • 22
    Devaux C, Moreau E, Goyffon M, Rochat H & Billiald P (2001) Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur J Biochem 268, 694702.
  • 23
    Lecut C, Schoolmeester A, Kuijpers MJ, Broers JL, van Zandvoort MA, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M & Heemskerk JW (2004) Principal role of glycoprotein I in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 24, 17271733.
  • 24
    Jandrot-Perrus M, Lagrue AH, Okuma M & Bon C. (1997) Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha2beta1. J Biol Chem 272, 2703527041.
  • 25
    Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M et al. (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295, 15311538.
  • 26
    De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM & Topol EJ (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293, 17591765.
  • 27
    Clemetson JM, Polgar J, Magnenat E, Wells TN & Clemetson KJ (1999) The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 274, 2901929024.
  • 28
    Laffly E & Sodoyer R (2005) Monoclonal and recombinant antibodies, 30 years after... Hum Antibodies 14, 3355.
  • 29
    Chen H, Locke D, Liu Y, Liu C & Kahn ML (2002) The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. J Biol Chem 277, 30113019.
  • 30
    Gardiner EE, Arthur JF, Kahn ML, Berndt MC & Andrews RK (2004) Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 104, 36113617.
  • 31
    Lagrue-Lak-Hal AH, Debili N, Kingbury G, Lecut C, Le Couedic JP, Villeval JL, Jandrot-Perrus M & Vainchenker W (2001) Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J Biol Chem 276, 1531615325.
  • 32
    Ohlmann P, Hechler B, Ravanat C, Loyau S, Herrenschmidt N, Wanert F, Jandrot-Perrus M & Gachet C (2008) Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost. 6, 10031011.
  • 33
    Hwang WY & Foote J (2005) Immunogenicity of engineered antibodies. Methods 36, 310.
  • 34
    Curtis BR, Swyers J, Divgi A, McFarland JG & Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99, 20542059.
  • 35
    Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373, 759767.
  • 36
    Tsurushita N, Hinton PR & Kumar S (2005) Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36, 6983.
  • 37
    Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Desmet J & Deckmyn H (2006) Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost 96, 671684.
  • 38
    Lazar GA, Desjarlais JR, Jacinto J, Karki S & Hammond PW (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 44, 19861998.
  • 39
    Jones PT, Dear PH, Foote J, Neuberger MS & Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522525.
  • 40
    Verhoeyen M, Milstein C & Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239, 15341536.
  • 41
    Caldas C, Coelho V, Kalil J, Moro AM, Maranhão AQ & Brígido MM (2003) Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Mol Immunol 39, 941952.
  • 42
    Gonzales NR, Padlan E, De Pascalis R, Schuck P, Schlom J & Kashmiri SV (2004) SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol Immunol 41, 863872.
  • 43
    MacArthur MW & Thornton JM (1999) Protein side-chain conformation: a systematic variation of chi 1 mean values with resolution – a consequence of multiple rotameric states? Acta Crystallogr D Biol Crystallogr 55, 9941004.
  • 44
    Honegger A & Pluckthun A (2001) The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J Mol Biol 309, 687699.
  • 45
    Tramontano A, Chothia C & Lesk AM (1990) Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 215, 175182.
  • 46
    Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML & Bluestone JA (1992) Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 148, 27562763.
  • 47
    Humphreys DP & Glover DJ (2001) Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr Opin Drug Discov Devel 4, 172185.
  • 48
    Carson KL (2005) Flexibility – the guiding principle for antibody manufacturing. Nat Biotechnol 23, 10541058.
  • 49
    Aubrey N, Devaux C, Sizaret PY, Rochat H, Goyffon M & Billiald P (2003) Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell Mol Life Sci 60, 617628.
  • 50
    Wu TT & Kabbat EA (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 132, 211250.
  • 51
    Sharp PM & Li WH (1986) Codon usage in regulatory genes in Escherichia coli does not reflect selection for ‘rare’ codons. Nucleic Acids Res 14, 77377749.
  • 52
    Appel RD, Bairoch A & Hochstrasser DF (1994) A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. Trends Biochem Sci 19, 258260.
  • 53
    Lecut C, Feijge MA, Cosemans JM, Jandrot-Perrus M & Heemskerk JW (2005) Fibrillar type I collagens enhance platelet-dependent thrombin generation via glycoprotein VI with direct support of alpha2beta1 but not alphaIIbbeta3 integrin. Thromb Haemost 94, 107114.
  • 54
    Hemker HC, Giesen PL, Ramjee M, Wagenvoord R & Béguin S (2000) The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 83, 589591.